- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01252966
Cognitive Training for Nicotine Dependence
12 janvier 2017 mis à jour par: University of Pennsylvania
This randomized clinical trial tested the effects of a computerized (web-based) cognitive training intervention on smoking cessation.
All participants received 8 weeks of standard nicotine patch therapy, smoking cessation counseling, and were randomized to 1 of 2 different training programs: cognitive training vs. control training.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Réel)
213
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Center for Interdiscplinary Research on Nicotine Addiction, University of Pennsylvania
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 65 ans (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion:
- Healthy male and female treatment-seeking smokers who are between 18 and 65 years of age and self-report smoking at least 5 cigarettes (menthol and/or non-menthol) per day for at least the last 6 months
- Plan to live in the area for at least the next 8 months
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and HIPAA form
- Able to communicate fluently in English (speaking, writing, and reading)
- Have uninterrupted access to a home computer with sound capabilities, keyboard, mouse, and active Internet connection
- Provide a Carbon Monoxide (CO) breath test reading greater than or equal to 8 parts per million (ppm) at Intake Visit
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Cognitive Training
Participants in this arm received computerized cognitive training in addition to nicotine patch and smoking cessation counseling.
|
The computerized cognitive training intervention is a 12-week standardized course of internet-based computerized cognitive exercises designed to enhance executive cognitive function.
|
|
Comparateur placebo: Control Training
Participants in this arm received computerized control training in addition to nicotine patch and smoking cessation counseling
|
The computerized control training intervention is a 12-week standardized course of internet-based deep breathing exercises which does not contain the cognitive exercises designed to enhance executive cognitive function.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Point-prevalence Abstinence at End of Treatment
Délai: End of treatment (Week 12)
|
Daily smoking, from the Target Quit Date to End of Treatment (EOT), was assessed by a validated timeline follow-back measure.
Based on guidelines for smoking cessation trials, the primary outcome was 7-day point prevalence abstinence at EOT, and abstinence was defined as no self-reported smoking (even a puff) for at least 7 days, with in-person verification by carbon monoxide breath levels (CO <8ppm).
Following standard convention, participants who withdrew or were lost to follow-up were considered smokers.
|
End of treatment (Week 12)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Point-prevalence Abstinence at 6-month Follow-up
Délai: 6 month follow-up
|
Daily smoking from the Target Quit Date to 6 month follow-up was assessed by a validated timeline follow-back measure.
Based on guidelines for smoking cessation trials, the secondary outcome was 7-day point prevalence abstinence at the 6 month follow-up, and abstinence was defined as no self-reported smoking (even a puff) for at least 7 days, with in-person verification by carbon monoxide breath levels (CO <8ppm).
Following standard convention, participants who withdrew or were lost to follow-up were considered smokers.
|
6 month follow-up
|
|
Cognitive Performance (Working Memory)
Délai: Baseline and Week 12 (EOT)
|
Change in performance on the Digit Span Forward task (working memory) between Baseline and End of Treatment (Week 12).
In this task, participants are presented with a series of digits on the computer screen at one second intervals.
Participants are then required to enter the digits in order.
The number of digits in each series ranges from 3 to 7, and the maximum recall span is the length of the largest series entered correctly.
The outcome measure is the change score (calculated by subtracting the Baseline score from the end of treatment score).
Change scores can range from -4 to 4. Negative numbers indicate worse performance at EOT; positive numbers indicate better performance at EOT; and 0 indicates no change.
|
Baseline and Week 12 (EOT)
|
|
Cognitive Performance (Response Inhibition)
Délai: Baseline and Week 12 (EOT)
|
Change in performance on the Go/No-Go Task (response inhibition) between Baseline and End of Treatment (Week 12).
In this task, participants are presented with a series of stimuli (the word "PRESS" in either green or red).
Participants are instructed to respond by pressing the spacebar when the stimulus is green, and to withhold a response when the stimulus is red.
The outcome is the change in number of commission errors (failure to withhold a response to a red stimulus) from EOT minus baseline.
The potential range for the change score is -42 to 42.
Negative numbers indicate a decrease in the number of commission errors (improved performance) from baseline to EOT; positive numbers indicate an increase in commission errors (worse performance); 0 indicates no change.
|
Baseline and Week 12 (EOT)
|
|
Cognitive Performance (Attention)
Délai: Baseline and Week 12 (EOT)
|
Change in performance on the Continuous Performance Task (attention) between Baseline and End of Treatment (Week 12).
In this task, participants are presented with a series of letters at 2.5s intervals and are instructed to respond by pressing the space bar if the same letter appears twice in a row.
The outcome is the change in the number of commission errors (the number of times the participant responded to a non-target at EOT minus baseline).
There are a total of 125 trials, with 20 target trials (response required) and 85 non-target trials (no response required); therefore the possible range for the change score is -85 to 85. Negative numbers indicate a decrease in commission errors (better performance at EOT compared to baseline); positive numbers indicate an increase in commission errors (worse performance at EOT compared to baseline); and 0 indicates no change.
|
Baseline and Week 12 (EOT)
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Chercheur principal: Caryn Lerman, PhD, University of Pennsylvania
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 mars 2011
Achèvement primaire (Réel)
1 septembre 2015
Achèvement de l'étude (Réel)
1 septembre 2015
Dates d'inscription aux études
Première soumission
1 décembre 2010
Première soumission répondant aux critères de contrôle qualité
1 décembre 2010
Première publication (Estimation)
3 décembre 2010
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
16 janvier 2017
Dernière mise à jour soumise répondant aux critères de contrôle qualité
12 janvier 2017
Dernière vérification
1 janvier 2017
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 812429
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .